IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: CHISM, B.

Date: May 31, 2005

Atty.'s Docket: SZARDENINGS=1

Washington, D.C.

4. In re Application of: SZARDENINGS, et al. Art Unit: 1654

Serial No.: 09/674,733

Filed: May 2, 2001

For: MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS

Confirmation No.: 3759

U.S. Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street

Alexandria, VA 22314

_ in the above-identified application. Transmitted herewith is an [XX] Amendment [XX] Szardenings Declaration

[] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.

Small entity status of this application under 37 CFR 1.9 and 1.27 has been previously asserted.

A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)			(Col. 2) (Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fee	Rate	Additional Fee
Total	43	Minus	64	0	x 25	\$	x 50	\$
Indep.	4	Minus	3	1	x100	ş	x200	\$200.00
First Presentation of Multiple Dependent Claim 180					180	\$	+360	\$
TOTAL ADDITIONAL CLAIMS FEE						\$	Total	\$200.00

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. I of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity Other Than Small Entity Response Filed Within Response Filed Within [] First - \$ 120.00 [] First - \$ 60.00] Second -\$ 225.00 [XX] Second - \$ 450.00 ſ - \$ 510.00 Third - \$1020.00 [Third Fourth \$ 795.00] Fourth - \$1590.00 - \$1080.00 Fifth - \$2160.00 l Fifth 1

[] Less fees (\$) already paid for months extension of time on

[] Please charge my Deposit Account No. 02-4035 in the amount of \$______. A duplicate copy of this sheet is attached.

[XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$650.00 is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case.

This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

06/02/2005 MBEYENE1 00000052 09674733

450.00 OP 01 FC:1252

Facsimile: (202) 737-3528 (202) 628-5197 Telephone:

BROWDY AND NEIMARK? P.L.L.C. Attorneys for Applicant(s)

Registrate No. 28,005

G:\ipc\n-q\Plou\Szardenings1\pto cover3.wpd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PARTIE Application of: SZARDENINGS, et al. Serial No.: 09/674,733 Washington, D.C. Filed: May 2, 2001 For: MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS Confirmation No.: 3759

AMENDMENT UNDER RULE 1.115

U.S. Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

In response to the nonfinal action mailed December 28, 2004, please enter the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 12 of this paper.

06/02/2005 MBEYENE1 00000052 09674733

02 FC:1201

200.00 OP